Protagonist Therapeutics PTGX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $56.37M+99.0% | $7.44M-95.6% | $4.71M+0.8% | $5.55M+33.1% | $28.32M-88.9% | ||
| $46.74M+30.2% | $46.36M+32.8% | $40M+11.2% | $37.04M+10.5% | $35.89M+6.4% | ||
| $13.28M+13.1% | $11.43M+27.7% | $11.13M+9.6% | $10.55M+11.8% | $11.74M-21.3% | ||
| $60.02M+26.0% | $57.79M+31.8% | $51.13M+10.9% | $47.59M+10.8% | $47.63M-2.1% | ||
| $60.02M+26.0% | $57.79M+31.8% | $51.13M+10.9% | $47.59M+10.8% | $47.63M-2.1% | ||
| -$3.65M+81.1% | -$50.36M-140% | -$46.42M-12.0% | -$42.04M-8.4% | -$19.31M-109% | ||
| -6.5%+61.7pp | -677.1%-751pp | -985.2%-98.5pp | -758%+173pp | -68.2%-149pp | ||
| $5.88M-22.4% | $6.76M-1.3% | $7.05M-8.2% | $7.41M0.0% | $7.57M+73.1% | ||
| $53K-35.4% | —— | $33K-76.6% | $36K-62.9% | $82K+532% | ||
| $2.28M+120% | -$43.72M-133% | -$39.34M-17.0% | -$34.6M-10.6% | -$11.66M-106% | ||
| -$1.5M— | $666K-66.5% | $0+100% | $172K+125% | $0-100% | ||
| $3.78M+132% | -$44.38M-134% | -$39.34M-18.5% | -$34.77M-13.6% | -$11.66M-106% | ||
| 6.7%+47.9pp | -596.8%-674pp | -834.9%-124pp | -627%+108pp | -41.2%-122pp | ||
| $0.05+126% | -$0.70-135% | -$0.62-14.8% | -$0.55-10.0% | -$0.19-106% | ||
| $0.06+132% | -$0.70-133% | -$0.62-14.8% | -$0.55-10.0% | -$0.19-106% | ||
| 70.5M+12.0% | 63.6M-2.3% | 63.8M+3.2% | 63.5M+3.6% | 63M-1.0% | ||
| 65.1M+3.4% | 63.6M+3.3% | 63.8M+3.2% | 63.5M+3.6% | 63M+3.5% | ||
| $53K-35.4% | —— | $33K-76.6% | $36K-62.9% | $82K+532% | ||
| -$3.65M+81.1% | -$50.36M-140% | -$46.42M-12.0% | -$42.04M-8.4% | -$19.31M-109% | ||
| -$3.24M+83.0% | -$49.98M-139% | -$46.06M-11.7% | -$41.74M-8.3% | -$19.07M-109% | ||
| -$3.24M+83.0% | -$49.98M-139% | -$46.06M-11.7% | -$41.74M-8.3% | -$19.07M-109% | ||
| -5.7%+61.6pp | -672%-746pp | -977.5%-95.8pp | -752.6%+173pp | -67.3%-148pp | ||
| -$3.65M+81.1% | -$50.36M-140% | -$46.42M-12.0% | -$42.04M-8.4% | -$19.31M-109% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Protagonist Therapeutics's revenue?
- Protagonist Therapeutics (PTGX) generated $74.1M in revenue over the trailing twelve months, down 64.4% year over year.
- Is Protagonist Therapeutics profitable?
- Protagonist Therapeutics is not currently profitable: it reported a net loss of $114.7M over the trailing twelve months, a -154.9% net margin.
- What is Protagonist Therapeutics's earnings per share?
- Protagonist Therapeutics's diluted EPS over the trailing twelve months is $-1.82.
- Where does Protagonist Therapeutics's income statement data come from?
- Every line is extracted from Protagonist Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
